Glaucoma (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma – Drugs In Development, 2021, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 23, 23, 13, 3, 79, 20 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

4B Technologies (Suzhou) Co Ltd

AbbVie Inc

AC Immune SA

Adtech Pharma Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Amgen Inc

Annexon Inc

Annovis Bio Inc

Arctic Vision Shanghai Biotechnology Co Ltd

Asha Vision LLC

Astellas Pharma Inc

Betaliq Inc

Better Life Pharmaceuticals Inc

Bial – Portela & Ca SA

BioAxone BioSciences Inc

Biozeus Pharmaceutical SA

Califia Bio Inc

Calpain Therapeutics Pty Ltd

Cellix Bio Pvt Ltd

Certa Therapeutics Pty Ltd

Chong Kun Dang Pharmaceutical Corp

Cloudbreak Therapeutics LLC

D. Western Therapeutics Institute Inc

Deha Pharmaceutical LLC

Dhp Korea Ltd

Disarm Therapeutics Inc

Dompe Farmaceutici SpA

DTx Pharma Inc

Emerald Organic Products Inc

Envisia Therapeutics Inc

Evotec SE

EyePoint Pharmaceuticals Inc

Eyevensys SAS

Fortress Biotech Inc

Future Medicine Co Ltd

Galimedix Therapeutics Ltd

Gene Signal International SA

Glaukos Corp

Graybug Vision Inc

Guangzhou Cellprotek Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Gurus BioPharm

Handok Inc

HitGen Inc

HK inno.N Corp

ID Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

InMed Pharmaceuticals Inc

Inspyr Therapeutics Inc

Intratus Inc

Isarna Therapeutics GmbH

jCyte Inc

Jenivision Inc

Kedalion Therapeutics Inc

Kodiak Sciences Inc

Kowa Co Ltd

Kukje Pharmaceutical Industry Co Ltd

Kyorin Pharmaceutical Co Ltd

Kyoto Drug Discovery & Development Co Ltd

Laboratoires Thea SA

Laboratorios Salvat SA

Laboratorios Sophia SA de CV

LayerBio Inc

Lee's Pharmaceutical Holdings Ltd

Luminus Biosciences Inc

Matrix Biomed Inc

MediPrint Ophthalmics Inc

MimeTech Srl

Mitotech SA

MyX Therapeutics Inc

NeurAegis Inc

Neuraly Inc

Neurim Pharmaceuticals Ltd

Neurizon Pharma GBR

Neuroptika Inc

NeuroScientific Biopharmaceuticals Ltd

NicOx SA

NoNO Inc

Novaliq GmbH

Novartis AG

Noveome Biotherapeutics Inc

Novoron Bioscience Inc

OccuRx Pty Ltd

Ocular Therapeutix Inc

Oculo Therapy LLC

Ocuphire Pharma Inc

Oncolys BioPharma Inc

ONL Therapeutics Inc

Palo BioFarma SL

pH Pharma Co Ltd

Pinotbio Inc

Profarma

Q BioMed Inc

Qlaris Bio Inc

Quark Pharmaceuticals Inc

Qurgen Inc

Radikal Therapeutics Inc

ReNetX Bio

Reven Pharmaceuticals Inc

Ripple therapeutics Corp

Santen Pharmaceutical Co Ltd

SIFI SpA

Skye Bioscience Inc

Stuart Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

Sun Pharmaceutical Industries Ltd

Sustained Nano Systems LLC

Sylentis SAU

TaeJoon Pharmaceuticals Co Ltd

TALLC Corp Inc

TearClear Corp

Teraclon IDF SL

TikoMed AB

Toa Eiyo Ltd

Topadur Pharma AG

ViSci Ltd

Viva Vision Biotech

Whitecap Biosciences LLC

Table of Contents

Table of Contents

Introduction

Glaucoma - Overview

Glaucoma - Therapeutics Development

Glaucoma - Therapeutics Assessment

Glaucoma - Companies Involved in Therapeutics Development

Glaucoma - Drug Profiles

Glaucoma - Dormant Projects

Glaucoma - Discontinued Products

Glaucoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Glaucoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Glaucoma – Pipeline by 4B Technologies (Suzhou) Co Ltd, 2021

Glaucoma – Pipeline by AbbVie Inc, 2021

Glaucoma – Pipeline by AC Immune SA, 2021

Glaucoma – Pipeline by Adtech Pharma Inc, 2021

Glaucoma – Pipeline by Aerie Pharmaceuticals Inc, 2021

Glaucoma – Pipeline by Aerpio Pharmaceuticals Inc, 2021

Glaucoma – Pipeline by Amgen Inc, 2021

Glaucoma – Pipeline by Annexon Inc, 2021

Glaucoma – Pipeline by Annovis Bio Inc, 2021

Glaucoma – Pipeline by Arctic Vision Shanghai Biotechnology Co Ltd, 2021

Glaucoma – Pipeline by Asha Vision LLC, 2021

Glaucoma – Pipeline by Astellas Pharma Inc, 2021

Glaucoma – Pipeline by Betaliq Inc, 2021

Glaucoma – Pipeline by Better Life Pharmaceuticals Inc, 2021

Glaucoma – Pipeline by Bial – Portela & Ca SA, 2021

Glaucoma – Pipeline by BioAxone BioSciences Inc, 2021

Glaucoma – Pipeline by Biozeus Pharmaceutical SA, 2021

Glaucoma – Pipeline by Califia Bio Inc, 2021

Glaucoma – Pipeline by Calpain Therapeutics Pty Ltd, 2021

Glaucoma – Pipeline by Cellix Bio Pvt Ltd, 2021

Glaucoma – Pipeline by Certa Therapeutics Pty Ltd, 2021

Glaucoma – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Glaucoma – Pipeline by Cloudbreak Therapeutics LLC, 2021

Glaucoma – Pipeline by D. Western Therapeutics Institute Inc, 2021

Glaucoma – Pipeline by Deha Pharmaceutical LLC, 2021

Glaucoma – Pipeline by Dhp Korea Ltd, 2021

Glaucoma – Pipeline by Disarm Therapeutics Inc, 2021

Glaucoma – Pipeline by Dompe Farmaceutici SpA, 2021

Glaucoma – Pipeline by DTx Pharma Inc, 2021

Glaucoma – Pipeline by Emerald Organic Products Inc, 2021

Glaucoma – Pipeline by Envisia Therapeutics Inc, 2021

Glaucoma – Pipeline by Evotec SE, 2021

Glaucoma – Pipeline by EyePoint Pharmaceuticals Inc, 2021

Glaucoma – Pipeline by Eyevensys SAS, 2021

Glaucoma – Pipeline by Fortress Biotech Inc, 2021

Glaucoma – Pipeline by Future Medicine Co Ltd, 2021

Glaucoma – Pipeline by Galimedix Therapeutics Ltd, 2021

Glaucoma – Pipeline by Gene Signal International SA, 2021

Glaucoma – Dormant Projects, 2021

Glaucoma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Glaucoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports